1 / 8

Higher Efficacy & Lower Toxicity with Terbium-161

The presentation compares Tb-161 with Lu-177, showcasing how Tb-161 delivers more radiation to tumors with less damage to healthy organs. Backed by data from the VIOLET trial, it underscores Tb-161u2019s superior therapeutic efficacy and safety profile.

Nuclearmedicinetherapy
Download Presentation

Higher Efficacy & Lower Toxicity with Terbium-161

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear Medicine Centre FMRi Gurugram INDIA Dr. Ishita B Sen Higher Efficacy & Lower Toxicity with Terbium-161 www.nuclearmedicinetherapy.in

  2. Introduction to Terbium-161 (Tb-161) • Tb-161 is being evaluated as a next-generation therapy for mCRPC • Investigated in the VIOLET trial (ClinicalTrials.gov ID: NCT05521412) • Shows better efficacy and lower toxicity than Lu-177

  3. Limitations of Lu-177 • Emits beta particles with ~0.7 mm pathlength • Effective for large tumors • Limited reach fails to target micrometastases or single tumor cells

  4. How Tb-161 is Different • Emits: • Beta particles • Auger electrons • Conversion electrons • Radiation effective over nanometer to micrometer range • Targets micrometastases with precision

  5. Better Energy Delivery • Tb-161 delivers 35–40% more absorbed energy per decay than Lu-177 • More focused radiation to tumor cells • Less damage to healthy tissues (e.g., kidneys, salivary glands)

  6. SPECT/CT-Based Dosimetry in VIOLET Trial • Advanced imaging confirms: • Higher tumor dose with Tb-161 • Maintained safety thresholds in healthy organs • No unexpected toxicities reported

  7. Key Takeaway • Tb-161 is more precise and safer than Lu-177 • Targets micrometastatic cancer more effectively • A promising choice for advanced prostate cancer treatment Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

  8. For more information talk to Dr. Ishita B Sen today. dr.ishitasen@nuclearmedicinetherapy.in +91 8700 668 431 www.nuclearmedicinetherapy.in

More Related